What were the key takeaways from BrightSpring Health-U’s earnings call?

What guidance did BrightSpring Health-U's management provide for the next earnings period?

What were the key takeaways from BrightSpring Health-U's earnings call?

What is the revenue and EPS growth rate for BrightSpring Health-U year over year?

What does BrightSpring Health-U do and what are its main business segments?

Did BrightSpring Health-U beat or miss consensus estimates last quarter?

What is BrightSpring Health-U's gross profit margin?

What is the market's earnings forecast for BrightSpring Health-U next quarter?

- **Revenue Growth**: 28% YoY to $3.3 billion, with adjusted EBITDA up 37% to $160 million.
- **Segment Strength**: Pharmacy Solutions +31%, Specialty/Infusion +42%; Provider Services +9%, Home Health +12%.
- **Acquisition Impact**: Amedisys deal to be accretive in 2026, with 16-18 new drug launches in pipeline.
- **Financial Health**: Leverage at 3.3x, targeting below 3.0x; EBITDA margin expansion in both segments.


**【CEO Summary Section】**
- Total revenue reached $3.3 billion, a 28% year-over-year increase, with adjusted EBITDA of $160 million, up 37%.
- Pharmacy Solutions grew 31% to $3.0 billion, driven by 42% growth in Specialty and Infusion scripts. Provider Services revenue rose 9% to $367 million.
- Amedisys and LHC branch acquisitions are expected to close soon and be accretive in 2026. An Investor Day is scheduled for March 2026.

**【CFO Financial Commentary】**
- GAAP net income was $420 million, with Non-GAAP EPS at $0.30. Cash flow from operations was $108 million, and leverage improved to 3.3x, targeting below 3.0x by year-end.
- Pharmacy Solutions EBITDA margin was 4.8%, up 40 basis points, while Provider Services margin reached 16.5%, up 90 basis points.

**【Q&A Highlights】**
- **Drug Pipeline**: 16-18 new LDD launches expected over 12-18 months, with 145 therapies in the portfolio.
- **Amedisys Acquisition**: Expected to be accretive in 2026, with no material impact on 2025 results.
- **Generic Impact**: EBITDA per script growth of 32% due to specialty mix and generics, with sustained growth in specialty and infusion.
- **M&A Strategy**: Focused on tuck-in deals in target geographies, with no immediate large transactions.


BTSGU

BTSGU fundamentals

You can ask Aime